Imatinib

Overview

Imatinib is a tyrosine kinase inhibitor used in the treatment of multiple cancers, most notably chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). It works by inhibiting the BCR-ABL tyrosine kinase, which is critical for the proliferation of cancer cells.

API suppliers (10)

Suppliers of Imatinib backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• ACEBRIGHT INDIA PHARMA PRIVATE LTD2 active DMF
• FIS FABBRICA ITALIANA SINTETICI SPA2 active DMF
• Hetero Labs LimitedIndia2 active DMF
• Natco PharmaIndia1 active DMF
• Natco PharmaIndia1 active DMF
• Natco PharmaIndia1 active DMF
• Natco PharmaIndia1 active DMF
• WAVELENGTH ENTERPRISES LTDIsrael
• Intas Pharmaceuticals Ltd.India
• Cadila Healthcare LimitedIndia

Patent & exclusivity (US)

Per the FDA Orange Book (27 approved US products), the latest listed US patent on Imatinib expires 26 Apr 2040. Generic API sourcing typically opens up once these lapse.

Therapeutic areas